Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
Jaguar Health
JAGX
Jaguar Health
Concentrated Revenue Will Strain And Orphan Progress Will Brighten Outlook
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
20 Aug 25
Updated
20 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$16.00
89.0% undervalued
intrinsic discount
20 Aug
US$1.76
1Y
-94.0%
7D
-8.3%
Loading
1Y
-94.0%
7D
-8.3%
Author's Valuation
US$16.0
89.0% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$16.0
89.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-54m
82m
2015
2017
2019
2021
2023
2025
2027
2028
Revenue US$82.3m
Earnings US$19.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
39.33%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.32%
Calculation
US$19.11m
Earnings '28
x
5.67x
PE Ratio '28
=
US$108.33m
Market Cap '28
US$108.33m
Market Cap '28
/
4.78m
No. shares '28
=
US$22.67
Share Price '28
US$22.67
Share Price '28
Discounted to 2025 @ 12.32% p.a.
=
US$16.00
Fair Value '25
